MEI PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.105 USD | -1.74% |
|
-1.74% | -46.47% |
Presenter SpeechDaniel Gold (Executives)So thank you all for attending this morning. It's grea...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MEI Pharma, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing novel and differentiated cancer therapies. Its drug candidate pipeline includes Voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. Voruciclib is a potent and selective orally administered CDK9 inhibitor. Voruciclib is being studied in a Phase 1 trial evaluating dose and schedule in patients with acute myeloid leukemia (AML) and B-cell malignancies as a single-agent, and in combination with the B-cell lymphoma 2 (BCL) inhibitor venetoclax (marketed as Venclexta) in patients with AML. ME-344 is a novel mitochondrial inhibitor drug candidate that demonstrates tumor selective activity in pre-clinical studies. It targets the OXPHOS pathway involved in the production of adenosine triphosphate (ATP).
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.105
USD
Average target price
22.67
USD
Spread / Average Target
+630.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.47% | 21.05M | |
| +29.77% | 49.18B | |
| +1.00% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.99% | 18.71B | |
| +8.22% | 13.26B | |
| +32.41% | 12.32B | |
| -1.62% | 11.99B |
- Stock Market
- Equities
- MEIP Stock
- News MEI Pharma, Inc.
- Transcript : MEI Pharma, Inc. - Analyst/Investor Day
